Unicycive Therapeutics (UNCY) Capital Expenditures (2022 - 2026)
Unicycive Therapeutics' (UNCY) quarterly Capital Expenditures came in at $8000.0 in Q1 2026, down 50.0% YoY from $16000.0 in Q1 2025, and up 300.0% on a QoQ basis from $2000.0 in Q3 2025.
Unicycive Therapeutics (UNCY) Capital Expenditures (2022 - 2026) Analysis & Trends
Unicycive Therapeutics (UNCY) has 4 years of Capital Expenditures data on file, last reported at $8000.0 in Q1 2026.
- Quarterly Capital Expenditures fell 50.0% year-over-year to $8000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $16000.0 (down 80.49% YoY) and the FY2025 annual result came in at $24000.0, down 66.67% from the prior year.
- Capital Expenditures grew to $8000.0 in Q1 2026, from $2000.0 in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $24000.0 in Q3 2024 to a low of $2000.0 in Q1 2022.
- A 4-year average of $11777.8 and a median of $8000.0 in 2026 frame the typical range for Capital Expenditures.
- The widest YoY moves for Capital Expenditures: up 166.67% in 2025, down 91.67% in 2025.
- Tracing UNCY's Capital Expenditures over 4 years: stood at $2000.0 in 2022, then jumped by 1000.0% to $22000.0 in 2024, then sank by 90.91% to $2000.0 in 2025, then jumped by 300.0% to $8000.0 in 2026.
- The last three Capital Expenditures figures came in at $8000.0 (Q1 2026), $2000.0 (Q3 2025), and $6000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 25.02 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 34.68 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -73.57 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.26 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 251.02 Mn |
| 10 | Unicycive Therapeutics | 151.01 Mn | 151.01 Mn | - | -1,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1,000.00 |
| Jun 30, 2026 | -1,000.00 |
| Mar 31, 2026 | 8,000.00 |
| Mar 31, 2026 | 8,000.00 |
| Sep 30, 2025 | 2,000.00 |
| Sep 30, 2025 | 2,000.00 |
| Jun 30, 2025 | 6,000.00 |
| Jun 30, 2025 | 6,000.00 |
| Mar 31, 2025 | 16,000.00 |
| Mar 31, 2025 | 16,000.00 |
| Dec 31, 2024 | 22,000.00 |
| Dec 31, 2024 | 22,000.00 |
| Sep 30, 2024 | 24,000.00 |
| Sep 30, 2024 | 24,000.00 |
| Jun 30, 2024 | 20,000.00 |
| Jun 30, 2024 | 20,000.00 |
| Mar 31, 2024 | 6,000.00 |
| Mar 31, 2024 | 6,000.00 |
| Mar 31, 2022 | 2,000.00 |
| Mar 31, 2022 | 2,000.00 |